Ardelyx Executives Face Securities Lawsuit Over Patient-Access Claims

The securities class action centers on a period between January 13, 2025, and August 6, 2026. Plaintiffs allege that while management publicly touted a robust commercial strategy to ensure patient access, the reality on the ground was far different. According to the complaint, stringent payer prior authorization requirements and step edit protocols were actively hindering new-patient starts and delaying prescription fulfillment for the company's two primary drugs.

Eric Foster, as Chief Commercial Officer, is specifically named as a defendant for his role in communicating these access strategies to the market. The lawsuit claims that despite directives telling physicians to prescribe freely, internal barriers were tightening. The impact of these alleged omissions became clear on August 6, 2026, when Ardelyx reduced its 2026 revenue guidance for IBSRELA and withdrew long-term projections for XPHOZAH. Following the disclosure, the company's stock price dropped from $4.87 to $4.00, marking an 18% decline in a single session.